Skip to content
drillr.ai
Sign up

ORKA

Oruka Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$74.48
+3.55%
Ask drillr

  • Sep 23, 2026, 11:00 UTC

    Oruka Therapeutics announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening responses without additional dosing after Week 4.

    Source:

  • Aug 25, 2026, 07:55 UTC

    BlackRock Inc. acquired a new minority stake in Oruka Therapeutics, Inc., purchasing 4,990,181 shares valued at approximately $474,916,000, representing about 8.27% ownership, as disclosed in a 13F filing.

    Source:

  • Aug 24, 2026, 00:00 UTC

    Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.

  • Aug 10, 2026, 00:00 UTC

    Oruka Therapeutics reported a net loss of $41.2 million for Q2 2026, with research and development expenses of $43.3 million and general and administrative expenses of $6.9 million.